Song 2019.

Methods	Study design: Randomised clinical trial Study duration: March 2015 to February 2016 Duration of follow‐up: 2 years Setting: Hospital
Participants	Inclusion criteria: Diagnosed as HCC by images; be willing to sign a written informed consent document Age (mean ± SD, range): TACE + RFA: 57.86 ± 5.42 years, 25‐70 years; TACE alone: 57.96 ± 5.85 years, 26‐71 years Male (n/total): TACE + RFA: 19/32; TACE alone: 20/32
Interventions	TACE + RFA group (n = 32): TACE: TACE comprised of hepatic arterial infusion chemotherapy and hepatic artery embolisation RFA: CT‐guided RFA. Multiple RFA treatments were performed for each patient, with an interval of 1‐2 weeks TACE group (n = 32): TACE comprised of hepatic arterial infusion chemotherapy and hepatic artery embolisation
Outcomes	Serum level of AFP Tumour diameter 1‐ and 2‐year survival rate
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.